Exagen Inc. (NASDAQ:XGN) Shares Sold by Nantahala Capital Management LLC

Nantahala Capital Management LLC trimmed its position in Exagen Inc. (NASDAQ:XGN) by 20.2% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 59,316 shares of the company’s stock after selling 14,990 shares during the period. Nantahala Capital Management LLC owned approximately 0.34% of Exagen worth $108,000 as of its most recent SEC filing.

Separately, RTW Investments LP grew its position in Exagen by 0.8% during the fourth quarter. RTW Investments LP now owns 1,504,602 shares of the company’s stock worth $2,994,000 after buying an additional 12,170 shares during the period. 75.25% of the stock is owned by hedge funds and other institutional investors.

Exagen Price Performance

XGN stock opened at $3.09 on Tuesday. The firm has a 50 day moving average of $2.80 and a 200-day moving average of $2.10. The company has a market cap of $53.74 million, a price-to-earnings ratio of -2.83 and a beta of 1.32. The company has a current ratio of 4.32, a quick ratio of 4.32 and a debt-to-equity ratio of 1.13. Exagen Inc. has a 12-month low of $1.30 and a 12-month high of $3.71.

Exagen (NASDAQ:XGN) last issued its quarterly earnings data on Monday, August 5th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.36) by $0.20. The firm had revenue of $15.06 million during the quarter, compared to analysts’ expectations of $13.20 million. Exagen had a negative return on equity of 78.90% and a negative net margin of 30.56%. During the same period in the previous year, the firm posted ($0.28) earnings per share. As a group, equities analysts expect that Exagen Inc. will post -1.02 EPS for the current fiscal year.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).